AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Portfolio
AbbVie announced its acquisition of biotech firm Apogee Therapeutics for $10.9 billion, marking the company's largest buyout in over five years and one of the biggest deals of the year in pharmaceuticals. The deal aims to strengthen AbbVie’s next-generation immunology pipeline with access to Apogee’s experimental drug candidate zumilokibart.
